References

russjcardiol

Российский кардиологический журнал

Russian Journal of Cardiology

1560-40712618-7620

«SILICEA-POLIGRAF» LLC

10.15829/1560-4071-2020-3-3786

russjcardiol-3786

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

Артериальная гипертензия у взрослых. Клинические рекомендации 2020

Arterial hypertension in adults. Clinical guidelines 2020

Кобалава

Ж. Д.

Kobalava

Zh. D.

cardiojournal@yandex.ru

Конради

А. О.

Konradi

A. O.

Недогода

С. В.

Nedogoda

S. V.

nedogodasv@rambler.ru

Шляхто

Е. В.

Shlyakhto

E. V.

Арутюнов

Г. П.

Arutyunov

G. P.

Баранова

Е. И.

Baranova

E. I.

Барбараш

О. Л.

Barbarash

O. L.

Бойцов

С. А.

Boitsov

S. A.

Вавилова

Т. В.

Vavilova

T. V.

Виллевальде

С. В.

Villevalde

S. V.

Галявич

А. С.

Galyavich

A. S.

Глезер

М. Г.

Glezer

M. G.

Гринева

Е. Н.

Grineva

E. N.

Гринштейн

Ю. И.

Grinstein

Yu. I.

Драпкина

О. М.

Drapkina

O. M.

Жернакова

Ю. В.

Zhernakova

Yu. V.

Звартау

Н. Э.

Zvartau

N. E.

Кисляк

О. А.

Kislyak

O. A.

Козиолова

Н. А.

Koziolova

N. A.

Космачева

Е. Д.

Kosmacheva

E. D.

Котовская

Ю. В.

Kotovskaya

Yu. V.

Либис

Р. А.

Libis

R. A.

Лопатин

Ю. М.

Lopatin

Yu. M.

Небиеридзе

Д. В.

Nebiridze

D. V.

Недошивин

А. О.

Nedoshivin

A. O.

Остроумова

О. Д.

Ostroumova

O. D.

Ощепкова

Е. В.

Oschepkova

E. V.

Ратова

Л. Г.

Ratova

L. G.

Скибицкий

В. В.

Skibitsky

V. V.

Ткачева

О. Н.

Tkacheva

O. N.

Чазова

И. Е.

Chazova

I. E.

Чесникова

А. И.

Chesnikova

A. I.

Чумакова

Г. А.

Chumakova

G. A.

Шальнова

С. А.

Shalnova

S. A.

Шестакова

М. В.

Shestakova

M. V.

Якушин

С. С.

Yakushin

S. S.

Янишевский

С. Н.

Yanishevsky

S. N.

Российское кардиологическое обществоРоссияRussian Society of CardiologyRussian Federation

2020

12032020

25337863786

Copyright © Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И., Барбараш О.Л., Бойцов С.А., Вавилова Т.В., Виллевальде С.В., Галявич А.С., Глезер М.Г., Гринева Е.Н., Гринштейн Ю.И., Драпкина О.М., Жернакова Ю.В., Звартау Н.Э., Кисляк О.А., Козиолова Н.А., Космачева Е.Д., Котовская Ю.В., Либис Р.А., Лопатин Ю.М., Небиеридзе Д.В., Недошивин А.О., Остроумова О.Д., Ощепкова Е.В., Ратова Л.Г., Скибицкий В.В., Ткачева О.Н., Чазова И.Е., Чесникова А.И., Чумакова Г.А., Шальнова С.А., Шестакова М.В., Якушин С.С., Янишевский С.Н., 2020

2020

Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И., Барбараш О.Л., Бойцов С.А., Вавилова Т.В., Виллевальде С.В., Галявич А.С., Глезер М.Г., Гринева Е.Н., Гринштейн Ю.И., Драпкина О.М., Жернакова Ю.В., Звартау Н.Э., Кисляк О.А., Козиолова Н.А., Космачева Е.Д., Котовская Ю.В., Либис Р.А., Лопатин Ю.М., Небиеридзе Д.В., Недошивин А.О., Остроумова О.Д., Ощепкова Е.В., Ратова Л.Г., Скибицкий В.В., Ткачева О.Н., Чазова И.Е., Чесникова А.И., Чумакова Г.А., Шальнова С.А., Шестакова М.В., Якушин С.С., Янишевский С.Н.

Kobalava Z.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I., Barbarash O.L., Boitsov S.A., Vavilova T.V., Villevalde S.V., Galyavich A.S., Glezer M.G., Grineva E.N., Grinstein Y.I., Drapkina O.M., Zhernakova Y.V., Zvartau N.E., Kislyak O.A., Koziolova N.A., Kosmacheva E.D., Kotovskaya Y.V., Libis R.A., Lopatin Y.M., Nebiridze D.V., Nedoshivin A.O., Ostroumova O.D., Oschepkova E.V., Ratova L.G., Skibitsky V.V., Tkacheva O.N., Chazova I.E., Chesnikova A.I., Chumakova G.A., Shalnova S.A., Shestakova M.V., Yakushin S.S., Yanishevsky S.N.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://russjcardiol.elpub.ru/jour/article/view/3786

Артериальная гипертензия у взрослых. Клинические рекомендации 2020

Arterial hypertension in adults. Clinical guidelines 2020

Артериальная гипертензиявзрослыеклинические рекомендации

arterial hypertensionadultsguidelines

References1

Sackett DL, Rosenberg WM, Gray JA et al. Evidence based medicine: what it is and what it isn’t. BMJ. 1996 Jan 13;312(7023):71-2.

Федеральный закон от 21.11.2011 № 323-ФЗ (ред. от 03.04.2017) “Об основах охраны здоровья граждан в Российской Федерации”.

Federal law No. 323-FZ of 21.11.2011 (ed. of 03.04.2017). On the basis of public health protection in the Russian Federation. (In Russ.)

Эпидемиологический словарь, 4-е издание. Под ред. Джона М. Ласта для Международной эпидемиологической ассоциации. М., 2009. 316 с.

Epidemiological dictionary, 4th edition. Edited by John M. last for the International epidemiological Association. Moscow, 2009. p. 316. (In Russ.)

Федеральное агентство по техническому регулированию и метрологии. Национальный стандарт Российской Федерации. ГОСТР 52379-2005. Надлежащая клиническая практика. Москва, 2005.

Federal Agency for technical regulation and Metrology. National standard of the Russian Federation. GOSTR 52379-2005. Good clinical practice. Moscow, 2005. (In Russ.)

Федеральный закон от 12.04.2010 № 61-ФЗ (ред. от 03.07.2016) “Об обращении лекарственных средств”.

Federal law of 12.04.2010 № 61-FZ (03.07.2016) On circulation of medicines. (In Russ.)

Jansen RW, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Int Med. 1995;122(4):286-95.

Малая медицинская энциклопедия. М.: Медицинская энциклопедия, 1991-96гг. [Электронный ресурс]. http://dic.academic.ru/dic.nsf/enc_medicine/28878/Синдром.

Small medical encyclopedia. Moscow: Medical encyclopedia, 1991-96. (In Russ.) http://dic.academic.ru/dic.nsf/enc_medicine/28878/Синдром.

Андреева Н. С., Реброва О. Ю., Зорин Н. А. и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012;4:10-24.

Andreeva NS, Rebrova OYu, Zorin NA, et al. Systems for evaluating the reliability of scientific evidence and the credibility of recommendations: comparative characteristics and prospects for unification. Medical technology. Evaluation and selection. 2012;4:10-24. (In Russ.)

Общероссийская общественная организация “Российская ассоциация геронтологов и гериатров”. Клинические рекомендации “Старческая астения”. 2018. http://uzrf.ru/userfiles/file/rokgvv/GeriatricCenter/01-1-astenia_recomend.pdf

All-Russian public organization “Russian Association of gerontologists and geriatricians”. Clinical recommendations “Senile asthenia”. 2018. (In Russ.) http://uzrf.ru/userfiles/file/rokgvv/GeriatricCenter/01-1-astenia_recomend.pdf

Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1•25 million people. Lancet. 2014 May 31;383(9932):1899-911. doi:10.1016/S0140-6736(14)60685-1.

Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J. 2013;34:951-61.

Elliott P, Stamler J, Nichols R, et al. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. BMJ. 1996;312:1249-53.

Кушаковский М. С. Эссенциальная гипертензия (гипертоническая болезнь). Причины, механизмы, клиника, лечение. СПб., 2002.

Kushakovsky MS. Essential hypertension (hypertension). The causes, mechanisms, clinical features, treatment. SPb., 2002. (In Russ.)

Ланг Г. Ф. Гипертоническая болезнь. М.: Медгиз, 1950. 459 с.

Lang GF. Hypertension. Moscow: Medgiz, 1950. p. 459. (In Russ.)

Постнов Ю. В., Орлов С. Н. Первичная гипертензия как патология клеточных мембран. М.: Медицина, 1987. 192 с.

Postnov YuV, Orlov SN. Primary hypertension as a pathology of cell membranes. Moscow: Meditsina, 1987. p. 192. (In Russ.)

Мясников А. Л. Гипертоническая болезнь. М.: Медгиз, 1954.

Myasnikov AL. Hypertension. Moscow: Medgiz, 1954. (In Russ.)

Муромцева Г. А., Концевая А. В., Константинов В. В., и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(6):4-11. doi:10.15829/1728-8800-2014-6-4-11.

Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012-2013 years. The results of ECVDRF. Cardiovascular Therapy and Prevention. 2014;13(6):4-11. (In Russ.) doi:10.15829/1728-8800-2014-6-4-11.

Бойцов С. А., Баланова Ю. А., Шальнова С. А., и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;4:4-14. doi:10.15829/1728-8800-2014-4-4-14.

Boytsov SA, Balanova YA, Shalnova SA, et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.) doi:10.15829/1728-8800-2014-4-4-14.

Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-23.

Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:243-50.

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041.

Чазова И. Е., Жернакова Ю. В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31. doi:10.26442/2075082X.2019.1.190179.

Chazova IE, Zhernakova YuV. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31. (In Russ.) doi:10.26442/2075082X.2019.1.190179.

Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.

Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Eur Heart J Cardiovasc Pharmacother. 2017;3:235-50.

Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA. Neurol. 2017;74:1246-54.

Rovio SP, Pahkala K, Nevalainen J, et al. Cardiovascular risk factors from childhood and midlife cognitive performance: the Young Finns study. J Am Coll Cardiol. 2017;69:2279-89.

Vishram JK, Borglykke A, Andreasen AH, et al, MORGAM Project. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) project. Hypertension. 2012;60:1117-23.

Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. Am J Hypertens. 2007;20:338-41.

Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation. 1999;100:354-60.

Domanski M, Mitchell G, Pfeffer M, et al, MRFIT Research Group. Pulse pressure and cardiovascular disease–related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 2002;287:2677-83.

Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Меморандум экспертов Российского кардиологического общества по рекомендациям Европейского общества кардиологов/Европейского общества по артериальной гипертензии по лечению артериальной гипертензии 2018 г. Российский кардиологический журнал. 2018;(12):131-42. doi:10.15829/1560-40712018-12-131-142.

Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology/European Society of Arterial Hypertension for the management of arterial hypertension. Russian Journal of Cardiology. 2018;(12):131-42. (In Russ.) doi:10.15829/1560-40712018-12-131-142.

Reino-Gonzalez S, Pita-Fernandez S, Seoane-Pillado T, et al. How in-office and ambulatory BP monitoring compare: A systematic review and meta-analysis. J Fam Pract. 2017 Jan;66(1):E5-E12.

Kollias A, Ntineri A, Stergiou GS. Association of night-time home blood pressure with nighttime ambulatory blood pressure and target-organ damage: a systematic review and metaanalysis. J Hypertens. 2017 Mar;35(3):442-52. doi: 10.1097/HJH.0000000000001189.

Fagard RH, Celis H, Thijs L, et al. Daytime and night–time blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51:55-61.

Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens. 2012;30:449-56.

Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension. 2006;47:846-53.

Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension vs. true normotension: a meta-analysis. J Hypertens. 2007;25:2193-219.

Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35:1245-54.

Albasri A, OʼSullivan JW, Roberts NW, et al. A comparison of blood pressure in community pharmacies with ambulatory, home and general practitioner office readings: systematic review and meta-analysis. J Hypertens. 2017 Oct;35(10):1919-1928. doi:10.1097/HJH.0000000000001443.

Clark CE, Taylor RS, Shore AC, et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet. 2012;379:905-14.

Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777-83.

Shi Y, Zhou W, Liu X, et al. Resting heart rate and the risk of hypertension and heart failure: a dose-response meta-analysis of prospective studies. J Hypertens. 2018 May;36(5):9951004. doi:10.1097/HJH.0000000000001627.

Salles GF, Reboldi G, Fagard RH, et al. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the Ambulatory Blood pressure Collaboration in patients with Hypertension (ABC-H) meta-analysis. Hypertension. 2016;67:693-700.

Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens. 2012;30:449-56.

Tucker KL, Sheppard JP, Stevens R, et al. Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis. PLoS Med. 2017;14:e1002389.

Parati G, Stergiou G, O’Brien E, et al, European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32:1359-66.

Sehestedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J. 2010;31:883-91.

Volpe M, Battistoni A, Tocci G, et al. Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. J Hypertens. 2012;30:1056-64.

Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 Jun;24(11):987-1003.

Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis. 1986;39:809-21.

Friedman GD, Selby JV, Quesenberry CP Jr, et al Precursors of essential hypertension: body weight, alcohol and salt use and parental history of hypertension. Prev Med 1988;17:387-402.

Дедов И. И., Шестакова М. В., Майоров А. Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова 9-й выпуск. Сахарный диабет. 2019;22(1S1):1-144.

Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Edited by Dedov I. I., Shestakova M. V., Mayorov A. Yu. 9th edition. Diabetes mellitus. 2019;22(1S1):1-144. (In Russ.)

Cosentino F, Grant P, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020 Jan 7;41(2):255-323. doi:10.1093/eurheartj/ehz486.

Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010 Jun 26;375(9733):2215-22. doi:10.1016/S0140-6736(10)60484-9.

Wilson PW, Cupples CF, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Amer. Heart J. 1991;121:586-90.

Izzo R, de Simone G, Trimarco V, et al. Hypertensive target organ damage predicts incident diabetes mellitus. Eur Heart J. 2013 Nov;34(44):3419-26. doi:10.1093/eurheartj/eht281.

Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD–EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012 May 9;307(18):1941-51. doi:10.1001/jama.2012.3954.

Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-67.

De Haan MW, Kroon AA, Flobbe K, et al. Renovascular disease in patients with hypertension: detection with duplex ultrasound. J Hum Hypertens. 2002 Jul;16(7):501-7.

Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012 Nov 10;380(9854):1649-61. doi:10.1016/S0140-6736(12)61272-0.

Van Der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011 Jun;79(12):1341-52. doi:10.1038/ki.2010.536.

Earley A, Miskulin D, Lamb EJ, et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med. 2012;156:785-95.

Zachrisson K, Herlitz H, Lonn L, et al. Duplex ultrasound for identifying renal artery stenosis: direct criteria re-evaluated. Acta Radiol. 2017 Feb;58(2):176-82. doi:10.1177/0284185116641345.

Matsushita K, Coresh J, Sang Y, et al. Kidney measures beyond traditional risk factors for cardiovascular prediction: A collaborative meta-analysis. Lancet Diabetes Endocrinol. 2015 Jul;3(7):514-25. doi:10.1016/S2213-8587(15)00040-6.

Gerstein HC, Mann JF, Yi Q, Zinman B, et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-6.

Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012 Mar 28;307(12):1302-9. doi:10.1001/jama.2012.366.

Guo X, Zou L, Zhang X, et al. Prehypertension: a meta-analysis of the epidemiology, risk factors, and predictors of progression. Tex Heart Inst J. 2011;38(6):643-52.

Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens. 2003 Jul;17(7):471-80.

Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol. 2004 Jan 21;43(2):155-61.

Wang J, Qin T, Chen J, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014 Dec 1;9(12):e114259. doi:10.1371/journal.pone.0114259.

Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta‐analysis. Arthritis Care Res (Hoboken). 2011 Jan;63(1):10210. doi:10.1002/acr.20344.

Palmer TM, Nordestgaard BG, Benn M, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ. 2013 Jul 18;347:f4262. doi:10.1136/bmj.f4262.

Schillaci G, Battista F, Pucci G. A review of the role of electrocardiography in the diagnosis of left ventricular hypertrophy in hypertension. Journal of electrocardiology. 2012;45(6):617-23.

Kahn S, Frishman WH, Weissman S, et al. Left ventricular hypertrophy on electrocardiogram: prognostic implications from a 10-year cohort study of older subjects: a report from the Bronx Longitudinal Aging Study. J Am Geriatr Soc. 1996;44:524-9.

Lonn E, Mathew J, Pogue J, et al. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. Eur J Cardiovasc Prevent Rehab. 2003;10:420-8.

Bacharova L, Schocken D, Estes EH, Strauss D. The role of ECG in the diagnosis of left ventricular hypertrophy. Curr Cardiol Rev. 2014;10:257-61.

Lehtonen AO, Puukka P, Varis J, et al. Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. J Hypertens. 2016;34:959-66.

Okin PM, Devereux RB, Jern S, et al. LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-9.

Vanezis AP, Bhopal R. Validity of electrocardiographic classification of left ventricular hypertrophy across adult ethnic groups with echocardiography as a standard. Journal of Electrocardiology. 2008;41(5):404-12.

Verdecchia P, Angeli F, Borgioni C. et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. American Journal of Hypertension. 2003;16(11):895-9.

Sundstrom J, Lind L, Arnlov J et al. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 2001;103:2346-51.

Palmieri V, Dahlof B, DeQuattro V et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999;34:1625-32.

Levy D, Garrison RJ, Savage DO et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.

Perrone-Filardi P, Coca A, Galderisi M, et al. Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). Eur Heart J Cardiovasc Imaging. 2017;18:945-60.

Mourad JJ, Cacoub P, Collet JP, et al. Screening of unrecognized peripheral arterial disease (PAD) using ankle–brachial index in high cardiovascular risk patients free from symptomatic PAD. J Vasc Surg. 2009 Sep;50(3):572-80. doi:10.1016/j.jvs.2009.04.055.

Vlachopoulos C, Aznaouridis K, Terentes-Printzios D, et al. Prediction of Cardiovascular Events and All-Cause Mortality With Brachial-Ankle Elasticity Index: A Systematic Review and Meta-Analysis. Hypertension. 2012;60(2):556-62.

Breslin DJ, Gifford RW Jr, Fairbairn JF II, Kearns TP. Prognostic importance of ophthalmoscopic findings in essential hypertension. JAMA. 1966;195:335-8.

Fuchs FD, Maestri MK, Bredemeier M, et al. Study of the usefulness of optic fundi examination of patients with hypertension in a clinical setting. Journal of human hypertension. J Hum Hypertens. 1995 Jul;9(7):547-51.

Dimmitt SB, West JN, Eames SM, et al. Usefulness of ophthalmoscopy in mild to moderate hypertension. Lancet. 1989;1:1103-6.

White PM, Wardlaw JM, Easton V. Can noninvasive imaging accurately depict intracranial aneurysms? A systematic review. Radiology. 2000;217(2):361-70.

Beynon R, Sterne JA, Wilcock G, et al. Is MRI better than CT for detecting a vascular component to dementia? A systematic review and meta-analysis. BMC Neurol. 2012 Jun 6;12:33. doi:10.1186/1471-2377-12-33.

Creavin ST, Wisniewski S, Noel-Storr AH, et al. Mini‐Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev. 2016 Jan 13;(1):CD011145. doi:10.1002/14651858.CD011145.pub2.

Tsoi KK, Chan JY, Hirai HW, et al. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med. 2015;175:1450-8.

Mach F, Baigent C, Catapano A, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020 Jan 1;41(1):111-188. doi:10.1093/eurheartj/ehz455.

Ebrahim S, Smith GD. Lowering blood pressure: a systematic review of sustained effects of non-pharmacological interventions. Journal of Public Health. 1998;20(4):441-8.

Sundstrom J, Arima H, Jackson R, et al. Blood Pressure-Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med. 2015;162:184-91.

Task FM, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315-381.

Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017;35:2150-60.

100

Beckett NS, Peters R, Fletcher AE et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-98.

101

Thijs L, Fagard R, Lijnen P, et al. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens. 1992 Oct;10(10):1103-9. doi:10.1097/00004872-199210000-00001.

102

Lonn EM, Bosch J, Lopez-Jaramillo P, et al. HOPE-3 Investigators. Blood–pressure lowering in. Intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009-20.

103

Williamson JD, Supiano MA, Applegate WB, et al. SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >75 years: a randomized clinical trial. JAMA. 2016;315:2673-82.

104

Beckett N, Peters R, Leonetti G, et al, HYVET Study Group. Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial. J Hypertens. 2014;32:1478-87.

105

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32:2285-95.

106

Patel A, MacMahon S, Chalmers J, et al, ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007 Sep 8;370(9590):829-40.

107

Hao G, Wang Z, Guo R, et al. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. BMC cardiovascular disorders. BMC Cardiovasc Disord. 2014 Oct 25;14:148. doi:10.1186/1471-2261-14-148.

108

Garrison SR, Kolber MR, Korownyk CS, et al. Blood pressure targets for hypertension in older adults. Cochrane Database Syst Rev. 2017 Aug 8;8:CD011575. doi:10.1002/14651858.CD011575.pub2.

109

Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. The Lancet. 2002;360(9349):1903-13.

110

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels — updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34:613-22.

111

Bohm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389:2226-37.

112

Kjeldsen SE, Berge E, Bangalore S, et al. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Press. 2016;25:83-92.

113

Mancia G, Kjeldsen SE, Zappe DH, et al. Cardiovascular outcomes at different on– treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J. 2016;37:955-64.

114

Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24:215-33.

115

Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2224-60. doi:10.1016/S0140-6736(12)61766-8.

116

He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2013;4:CD004937.

117

Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low-sodium diet vs. highsodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens. 2012;25:1-15.

118

Taylor RS, Ashton KE, Moxham T, et al. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am J Hypertens. 2011;24:843-53.

119

Aburto NJ, Ziolkovska A, Hooper L, et al. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ. 2013;346:f1326.

120

Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a metaanalysis of randomized controlled trials. Hypertension. 2001 Nov;38(5):1112-7.

121

Gay HC, Rao SG, Vaccarino V, Ali MK. Effects of different dietary interventions on blood pressure: systematic review and meta-analysis of randomized controlled trials. Hypertension. 2016 Apr;67(4):733-9. doi:10.1161/HYPERTENSIONAHA.115.06853.

122

Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a metaanalysis of randomized controlled trials. Hypertension. 2003;42:878-84.

123

Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71-82.

124

Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010 Dec 2;363(23):2211-9. doi:10.1056/NEJMoa1000367.

125

Leitzmann MF, Park Y, Blair A, et al. Physical activity recommendations and decreased risk of mortality. Arch Intern Med. 2007 Dec 10;167(22):2453-60.

126

Rossi A, Dikareva A, Bacon SL, Daskalopoulou SS. The impact of physical activity on mortality in patients with high blood pressure: a systematic review. J Hypertens. 2012 Jul;30(7):1277-88. doi:10.1097/HJH.0b013e3283544669.

127

Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ. 1989 Mar 25;298(6676):789-94.

128

He J, Vupputuri S, Allen K, et al. Passive smoking and the risk of coronary heart disease — a meta-analysis of epidemiologic studies. N Engl J Med. 1999 Mar 25;340(12):920-6.

129

Linneberg A, Jacobsen RK, Skaaby T, et al. Effect of smoking on blood pressure and resting heart rate: a mendelian randomization meta-analysis in the CARTA Consortium. Circ Cardiovasc Genet. 2015 Dec;8(6):832-41. doi:10.1161/CIRCGENETICS.115.001225.

130

Matsuzaki M, Ogihara T, Umemoto S, et al. Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29:1649-59.

131

MacDonald TM, Williams B, Webb DJ, et al. British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc. 2017;6:e006986.

132

Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012;59:1124-31.

133

Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010;28:1584-90.

134

Garjon J, Saiz LC, Azparren A, et al. First‐line combination therapy versus first‐line monotherapy for primary hypertension. Cochrane Database Syst Rev. 2017 Jan 13;1:CD010316. doi:10.1002/14651858.CD010316.pub2.

135

Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig. 2012;32:649-64.

136

Pongpanich P, Pitakpaiboonkul P, Takkavatakarn K, et al. The benefits of angiotensinconverting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. Int Urol Nephrol. 2018 Dec;50(12):2261-78. doi:10.1007/s11255-018-1991-x.

137

Williams B, MacDonald TM, Morant S, et al. British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, doubleblind, crossover trial. Lancet. 2015;386:2059-68.

138

Carey RM, Calhoun DA, Bakris GL. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 Nov;72(5):e53-e90.

139

Makani H, Bangalore S, Desouza KA, et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. 2013 Jan 28;346:f360. doi:10.1136/bmj.f360.

140

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure–lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs — overview and meta-analyses. J Hypertens 2015;33:1321–41.

141

Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens. 2005;23:2113-8.

142

Reboldi G, Angeli F, Cavallini C, et al. Comparison between angiotensin–converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26:1282-9.

143

Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens. 2016;34:1921-32.

144

Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011;123:1611-21.

145

Fried LF, Emanuele N, Zhang JH, et al. NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892-903.

146

Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.

147

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs — overview and meta-analyses. J Hypertens. 2015;33:195-211.

148

Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly–treated patients: a population-based study in Italy. J Hypertens. 2008;26:819-24.

149

Brown MJ, Williams B, Morant SV, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016;4:136-47.

150

Rimoldi SF, Messerli FH, Chavez P, et al. Efficacy and safety of calcium channel blocker/ diuretics combination therapy in hypertensive patients: a meta‐analysis. J Clin Hypertens (Greenwich). 2015 Mar;17(3):193-9. doi:10.1111/jch.12462.

151

Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009 Mar;122(3):290-300. doi:10.1016/j.amjmed.2008.09.038.

152

Kang S, Wu YF, An N, Ren M. A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril–indapamide combination as first-line treatment of hypertension. Clin Ther. 2004 Feb;26(2):257-70.

153

Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. The Lancet. 2010 Mar 13;375(9718):906-15. doi:10.1016/S01406736(10)60235-8.

154

Чазова И. Е., Мычка В. Б. Новые возможности в лечении больных с метаболическим синдромом: результаты исследования ALMAZ, Системные гипертензии. 2006;2:14-7.

Chazova IE, Mychka VB. New opportunities in the treatment of patients with metabolic syndrome: results of the ALMAZ study. Systemic hypertension. 2006;2:14-7. (In Russ.)

155

Chazova I, Schlaich MP. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY study. Int J Hypertens. 2013;2013:541689. doi:10.1155/2013/541689.

156

Rayner B. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? Current medical research and opinion. 2004;20,3:359-67.

157

Bhatt DL, Kandzari DE, O’Neill WW, et al. for the Symplicity HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-401.

158

Mathiassen ON, Vase H, Bech JN, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressurebased trial. J Hypertens. 2016;34:1639-47.

159

DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289:R633-R641.

160

Mahfoud F, Bohm M, Azizi M, et al. Proceedings from the European Clinical Consensus Conference for Renal Denervation: considerations on future clinical trial design. Eur Heart J. 2015;36:2219-27.

161

Narkiewicz K, Ratcliffe LE, Hart EC, et al. Unilateral carotid body resection in resistant hypertension: a safety and feasibility trial. JACC Basic Transl Sci. 2016;1:313-24.

162

Bohm M, Mahfoud F, Ukena C et al. GSR Investigators. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015;65:766-74.

163

Ng FL, Saxena M, Mahfoud F, et al. Device–based therapy for hypertension. Curr Hypertens Rep. 2016;18:61.

164

Burchell AE, Lobo MD, Sulke N, et al. Arteriovenous anastomosis: is this the way to control hypertension? Hypertension. 2014;64:6-12.

165

Kario K, Tomitani N, Kanegae H, et al. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring — The NOCTURNE Study. Circulation Journal. 2017;81;7:948-57.

166

Tsai WC, Wu HY, Peng YS, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med. 2017;177:792-9.

167

Jafar TH, Stark PC, Schmid CH, et al. AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244-52.

168

Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end–stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol. 2014;64:588-97.

169

Bakris GL, Sarafidis PA, Weir MR, et al. ACCOMPLISH Trial Investigators. Renal outcomes with different fixed–dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173-81.

170

Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-43.

171

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

172

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200.

173

Emdin CA, Callender T, Cao J, et al. Meta-analysis of large-scale randomized trials to determine the effectiveness of inhibition of the renin-angiotensin aldosterone system in heart failure. The American journal of cardiology. 2015;116(1):155-61. doi:10.1016/j.amjcard.2015.03.052.

174

Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur heart J. 2010;32(6):670-9.

175

Nanayakkara S, Kaye DM. Management of heart failure with preserved ejection fraction: a review. Clinical therapeutics. 2015;37(10):2186-98.

176

Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134(1):73-90. doi:10.1161/CIRCULATIONAHA.116.021884.

177

Shah RV, Akshay SD, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. Journal of cardiac failure. 2010;16(3):260-7.

178

Soliman EZ, Ambrosius WT, Cushman WC, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation. 2017:136(5):440-50.

179

Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. The American journal of medicine. 2003 Jul;115(1):41-6.

180

Dahlof B, Kjell P, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. 1992:95-110.

181

Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on. Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart. Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion. Cardiaca y Electrofisiologia (SOLEACE). Europace. 2017;19:891-911.

182

Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893-962.

183

Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Annals of internal medicine. 1999;131:492501;536,556.

184

Фибрилляция и трепетание предсердий у взрослых. Клинические рекомендации. Всероссийское научное общество специалистов поклинической электрофизиологии, аритмологии и электростимуляции. Общество специалистов по неотложной кардиологии. 2016. http://webmed.irkutsk.ru/doc/pdf/fedaf.pdf

Atrial fibrillation and flutter in adults. Clinical recommendations. All-Russian scientific society of specialists in clinical electrophysiology, Arrhythmology and electrical stimulation. Society of emergency cardiology specialists. 2016. (In Russ.) http://webmed.irkutsk.ru/doc/pdf/fedaf.pdf

185

Arima H, Chalmers J, Woodward M, et al. PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:1201-8.

186

Rodriguez-Luna D, Pineiro S, Rubiera M, et al. Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage. Eur J Neurol. 2013;20:1277-83.

187

Sakamoto Y, Koga M, Yamagami H, et al. Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement intracerebral hemorrhage study. Stroke. 2013;44:1846-51.

188

Anderson CS, Heeley E, Huang Y, et al. INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355-65.

189

Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375:1033-43.

190

Tsivgoulis G, Katsanos AH, Butcher KS, et al. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis. Neurology. 2014;83:1523-9.

191

Steiner T, Al-Shahi Salman R, Beer R, et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. International Journal of Stroke. 2014;9:840-55.

192

Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46:2032-60. doi:10.1161/STR.0000000000000069.

193

Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46-e138.

194

Lee M, Ovbiagele B, Hong KS, et al. Effect of blood pressure lowering in early ischemic stroke: meta-analysis. Stroke. 2015;46:1883-9.

195

Zhao R, Liu FD, Wang S, et al. Blood pressure reduction in the acute phase of an ischemic stroke does not improve shortor long-term dependency or mortality: a meta-analysis of current literature. Medicine (Baltimore). 2015;94:e896.

196

Ahmed N, Wahlgren N, Brainin M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke — International Stroke Thrombolysis Register (SITS–ISTR). Stroke. 2009;40:2442-9.

197

WuW, HuoX, ZhaoX, et al. Relationship between blood pressure and outcomes in acute ischemic stroke patients administered lytic medication in the TIMS — China Study. PLoS One. 2016;11:e0144260.

198

PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressurelowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. The Lancet. 2001;358,9287:1033-41.

199

White CL, Szychowski JM, Pergola PE, et al. Secondary Prevention of Small Subcortical Strokes Study Investigators. Can blood pressure be lowered safely in older adults with lacunar stroke? The Secondary Prevention of Small Subcortical Strokes study experience. J Am Geriatr Soc. 2015;63:722-29.

200

SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. New England Journal of Medicine. 2015;373(22):2103-16.

201

Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006;37,7:1933-40.

202

Lane DA, Lip GYH. Treatment of hypertension in peripheral arterial disease. Cochrane database of systematic reviews. 2013;12.

203

Vidal-Petiot E, Ford I, Greenlaw N, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. The Lancet. 2016;388(10056):2142-52.

204

Zanchetti A, Hennig M, Hollweck R et al. Baseline values but not treatment-induced changes incarotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation 2009;120:1084-90.

205

Zanchetti A, Crepaldi G, Bond MG, et al. PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS-a randomized double-blind trial. Stroke. 2004;35:2807-12.

206

Myou S, Fujimura M, Kamio Y, et al. Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. Am J Respir Crit Care Med. 2000;162:40-4.

207

Chiu KY, Li JG, Lin Y. Calcium channel blockers for lung function improvement in asthma: A systematic review and meta-analysis. Ann Allergy Asthma Immunol 2017;119(6):518-23.e3.

208

Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensinconverting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2012;12:263-77.

209

Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.

210

Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci (Lond). 2012;123(8):487-98.

211

Tanaka H, Teramoto S, Oashi K, et al. Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation. 2001;104(3):281-5.

212

Сукмарова З. Н., Литвин А. Ю., Чазова И. Е., Рогоза А. Н. Эффективность комплексной медикаментозной и CPAP-терапии у пациентов с артериальной гипертонией 2-3-й степени и тяжелой степенью синдрома обструктивного апноэ во время сна. Системные гипертензии. 2011;8(1):40.

Sukmarova ZN, Litvin AYu, Chazova IE, Rogoza AN. Effectiveness of complex medication and CPAP therapy in patients with arterial hypertension of the 2nd-3rd degree and severe obstructive sleep apnea syndrome. Systemic hypertension. 2011;8(1):40. (In Russ.)

213

Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on noncardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35:2383-431.

214

Futier E, Lefrant JY, Guinot PG, et al. Effect of individualized vs standard blood pressure management strategies on postoperative organ dysfunction among high-risk patients undergoing major surgery: a randomized clinical trial. JAMA. 2017;318:1346-57.

215

London MJ, Hur K, Schwartz GG, Henderson WG. Association of perioperative betablockade with mortality and cardiovascular morbidity following major non-cardiac surgery. JAMA. 2013;309:1704-13.

216

Andersson C, Merie C, Jorgensen M, et al. Association of beta-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwidecohort study. JAMA Intern Med. 2014;174:336-44.

217

Blessberger H, Kammler J, Domanovits H, et al. Perioperative beta–blockers for preventing surgery–related mortality and morbidity. Cochrane Database Syst Rev. 2018;3:CD004476.

218

Lederballe Pedersen O, Mikkelsen E, Lanng Nielsen J, Christensen NJ. Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin. Eur J Clin Pharmacol. 1979 Apr 17;15(3):215-7.

219

Gupta P, Patel P, Strauch B, et al. Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence. Hypertension. 2017;70:1042-8.

220

Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105:98-105.

221

Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistanthypertension: results from a randomized trial. Hypertension. 2009;54:475-81.

222

Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: a meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2017;39:257-63.

223

Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials. Heart Lung Circ. 2016;25:1021-30.

224

Huang Y, Huang W, Mai W, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens. 2017;35:677-88.

225

Briasoulis A, Androulakis E, Palla M, et al. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens. 2016;34:593-9.

226

Grassi G, Seravalle G, Trevano FQ, et al. Neurogenic abnormalities in masked hypertension. Hypertension. 2007;50:537-42.

227

Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med. 2018;378:1509-20.

228

Cuspidi C, Rescaldani M, Tadic M, et al. White-coat hypertension, as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a metaanalysis. J Hypertens. 2015;33:24-32.

229

Mancia G, Bombelli M, Facchetti R, et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens 2009;27:1672-8.

230

Tientcheu D, Ayers C, Das SR, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol 2015;66:2159-69.

231

Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226-32.

232

Thakkar HV, Pope A, Anpalahan M. Masked Hypertension: A Systematic Review. Heart. Lung and Circulation. 2019.

233

Ogedegbe G, Agyemang C, Ravenell JE. Masked hypertension: evidence of the need to treat. Curr Hypertens Rep. 2010;12:349-55.

234

Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. American journal of hypertension. 2011;24,1:52-8.

235

Agarwal R, Bills JE, Hecht TJ, Light RP. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension. 2011 Jan;57(1):29-38. doi:10.1161/HYPERTENSIONAHA.110.160911.

236

Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613-22.

237

Easterling T, Mundle S, Bracken H, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. The Lancet. 2019;394,10203:1011-21.

238

Ogihara T, Saruta T, Rakugi H, et al.; COLM Investigators. Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. Hypertens Res. 2015;38:89-96.

239

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14-effects of different classes of antihypertensive drugs in older and younger patients overview and meta-analysis. Journal of hypertension. 2018;36(8):1637-47.

240

Corrao G, Mazzola P, Monzio Compagnoni M, et al. Antihypertensive medications, loop diuretics, and risk of hip fracturein the elderly: a population-based cohort study of 81,617 Italian patients newly treated between 2005 and 2009. Drugs Aging. 2015;32:927-36.

241

Kjeldsen SE, Stenehjem A, Os I, et al. Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets. Blood Press. 2016;25:333-6.

242

Egan BM, Li J, Hutchison FN, Ferdinand KC. Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation. 2014;130(19):1692-9.

243

Liu X, Rodriguez CJ, Wang K. Prevalence and trends of isolated systolic hypertension among untreated adults in the United States. J Am Soc Hypertens. 2015;9(3):197-205.

244

Bavishi C, Goel S, Messerli FH. Isolated Systolic Hypertension: An Update After SPRINT Am J Med. 2016;129(12):1251-8.

245

Ekundayo OJ, Allman RM, Sanders PW, et al. Isolated systolic hypertension and incident heart failure in older adults: a propensity-matched study. Hypertension. 2009;53(3):458-65.

246

Li Y, Wei FF, Thijs L, et al. Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations. Circulation. 2014;130(6):466-74.

247

O’Rourke MF, Adji A. Guidelines on guidelines: focus on isolated systolic hypertension in youth. J Hypertens. 2013;31:649-54.

248

Yano Y, Stamler J, Garside DB, et al. Isolated systolic hypertension in young and middleaged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. J Am Coll Cardiol. 2015;65:327-35.

249

Penny JA, Halligan AW, Shennan AH, et al. Automated, ambulatory, or conventional blood pressure measurement in pregnancy: which is the better predictor of severe hypertension? Am J Obstet Gynecol. 1998;178:521-6.

250

Weitz C, Khouzami V, Maxwell K, Johnson JW. Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study. International Journal of Gynecology & Obstetrics. 1987;25,1:35-40.

251

Williams B, Mancia G, Spiering W, et al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood pressure. 2018;27,6:314-40.

252

Curtis KM, Mohllajee AP, Martins SL, Peterson HB. Combined oral contraceptive use among women with hypertension: a systematic review. Contraception. 2006;73,2:179-88.

253

Lubianca JN, Moreira LB, Gus M, Fuchs FD. Stopping oral contraceptives: an effective blood pressure–lowering intervention in women with hypertension. J Hum Hypertens. 2005;19:451-5.

254

Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation. 1996;94:483-9.

255

Dong W, Colhoun HM, Poulter NR. Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. J Hypertens. 1997;15:1063-8.

256

Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA. 2000;284:72-8.

257

World Health Organization. Medical eligibility criteria for contraceptive use. Third edition, 2004. http://apps.who.int/iris/bitstream/10665/42907/1/9241562668.pdf (date accessed June 28th 2018).

258

La Torre A, Giupponi G, Duffy D, et al. Sexual dysfunction related to drugs: a critical review. Part IV: cardiovascular drugs. Pharmacopsychiatry. 2015;48:1-6.

259

Pickering TG, Shepherd AM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens. 2004 Dec;17(12 Pt 1):1135-42.

260

Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep. 2007;9:320-8.

261

Abi Aad S, Pierce M, Barmaimon G, et al. Hypertension induced by chemotherapeutic and immunosuppresive agents: a new challenge. Crit Rev Oncol Hematol. 2015;93:28-35.

262

Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102:596-604.

263

Chang HM, Okwuosa TM, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol. 2017;70:2552-65.

264

Milan A, Puglisi E, Ferrari L, et al. Arterial hypertension and cancer. Int J Cancer 2014;134:2269-77.

265

Sever PS, Dahlof B, Poulter NR, et al. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lowerthanaverage cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.

266

Catapano AL, Graham I, De Backer G, et al. Authors/Task Force Members. ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37:2999-3058.

267

Fulcher J, O’Connell R, Voysey M, Emberson J, et al. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397-405.

268

Lip GY, Felmeden DC, Dwivedi G. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev. 2011;12:CD003186.

269

van den Born BJ, Lip GYH, Brguljan-Hitij J, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacotherapy 2018.

270

Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356:411-7.

271

Chester EM, Agamanolis DP, Banker BQ, Victor M. Hypertensive encephalopathy: a clinicopathologic study of 20 cases. Neurology. 1978;28:928-39.

272

van den Born BJ, Koopmans RP, Groeneveld JO, van Montfrans GA. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens. 2006;24:2299-304.

273

Cremer A, Amraoui F, Lip GY, et al. From malignant hypertension to hypertensionMOD: a modern definition for an old but still dangerous emergency. J Hum Hypertens. 2016;30:463-6.

274

Pinna G, Pascale C, Fornengo P, et al. Hospital admissions for hypertensive crisis in the emergency departments: a large multicenter Italian study. PLoS One. 2014;9:e93542.

275

van den Born BJ, Lowenberg EC, van der Hoeven NV, et al. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens. 2011;29:922-7.

276

Grassi D, O’Flaherty M, Pellizzari M, et al. Hypertensive urgencies in the emergency department: evaluating blood pressure response to rest and to antihypertensive drugs with different profiles. J Clin Hypertens (Greenwich). 2008;10:662-7.

277

Grossman A, Messerli FH, Grossman E. Drug induced hypertension — An unappreciated cause of secondary hypertension. Eur J Pharmacol. 2015;763:15-22.

278

Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review. J Hum Hypertens. 2008;22:596-607.

279

Amraoui F, Van Der Hoeven NV, Van Valkengoed IG, et al. Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case-control study. J Clin Hypertens (Greenwich). 2014;16:122-6.

280

Gonzalez R, Morales E, Segura J, et al. Long-term renal survival in malignant hypertension. Nephrol Dial Transplant. 2010;25:3266-272.

281

Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta‐analysis. Journal of the American Heart Association. 2013;2,1:e004473.

282

Julius S, Nesbitt SD, Egan BM, et al. Trial of Preventing Hypertension Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685-97.

283

Cook NR, Cutler JA, Obarzanek E et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334:885-8.

284

Viera AJ, Bangura F, Mitchell CM, et al. Do clinicians tell patients they have prehypertension? J Am Board Fam Med. 2011;24:117-8.

285

Gupta AK, McGlone M, Greenway FL, Johnson WD. Prehypertension in disease-free adults: a marker for an adverse cardiometabolic risk profile. Hypertens Res. 2010;33:905-10.

286

Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011;305:913-22.

287

Bosworth HB, Olsen MK, Grubber JM, et al. Two self–management interventions to improve hypertension control: a randomized trial. Annals of internal medicine. 2009;151,10:687-95.

288

Birtwhistle RV, Godwin MS, Delva MD, et al. Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners. BMJ.2004;328:204.

289

Fahey T, Schroeder K, Ebrahim S. Educational and organisational interventions used to improve the management of hypertension in primary care: a systematic review. Br J Gen Pract. 2005;55,520:875-82.

290

Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane database of systematic reviews. 2010;3.

291

Omboni S, Gazzola T, Carabelli G, Parati G. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013;31:455-68.

292

Duan Y, Xie Z, Dong F, et al. Effectiveness of home blood pressure telemonitoring: a systematic review and meta-analysis of randomised controlled studies. J Hum Hypertens. 2017;31:427-37.

293

Omboni S, Ferrari R. The role of telemedicine in hypertension management: focus on blood pressure telemonitoring. Curr Hypertens Rep. 2015;17:535.

294

Bray EP, Holder R, Mant J, McManus RJ. Does self–monitoring reduce bloodpressure? Meta-analysis with meta-regression of randomized controlled trials. Ann Med 2010;42:371-86.

295

Niiranen TJ, Hanninen MR, Johansson J, et al. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office bloodpressure: the Finn–Home study. Hypertension. 2010;55:1346-51.

296

Диспансерное наблюдение больных хроническими неинфекционными заболеваниями и пациентов с высоким риском их развития. Методические рекомендации. Под ред. С. А. Бойцова и А. Г. Чучалина. М.:2014. 112 с. URL: http://www.gnicpm.ru, http://www.ropniz.ru

Dispensary observation of patients with chronic non-infectious diseases and patients with a high risk of their development. Methodical recommendation. Edited by S. A. Boytsov and A. G. Chuchalin. Moscow: 2014. 112 p. (In Russ.) URL: http://www.gnicpm.ru , http://www.ropniz.ru

297

298

Jahromi AS, Cina CS, Liu Y, Clase CM. Sensitivity and specificity of color duplex ultrasound measurement in the estimation of internal carotid artery stenosis: a systematic review and meta-analysis. Journal of vascular surgery. 2005;41,6:962-72.

299

Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 — Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922-44.

300

Kelley GA, Kelley KA, Vu Tran Z. Aerobic exercise and resting blood pressure: a metaanalytic review of randomized, controlled trials. Preventive cardiology. 2001;4,2:73-80.

301

Semlitsch T, Jeitler K, Hemkens LG, et al. Increasing physical activity for the treatment of hypertension: a systematic review and meta-analysis. Sports medicine. 2013;43,10:1009-23.

302

Клинические рекомендации “алгоритмы специализированной медицинской помощи больным сахарным диабетом”. Под ред. И. И. Дедова, М.В. Шестаковой, А. Ю. Майорова, 9 выпуск, дополненный. Москва 2019.

Clinical recommendations. Algorithms for specialized medical care for patients with diabetes mellitus. Ed. I. I. Dedov, M. V. Shestakova, A. Yu. Mayorov, 9 issue, supplemented. Moscow 2019. (In Russ.)

The authors declare that there are no conflicts of interest present.